People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $432.7M | 2024 |
| Attralus, Inc. | — | Biotechnology | Series D+ | $172.8M | $708.5M | 2021 |
| Aeovian Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $125.0M | $297.5M | 2019 |
| Elevation Oncology, Inc. | — | Pharma | Series C | $70.5M | $2.0B | 2020 |
| Entact Bio, Inc. | — | Biotechnology | Series C | $40.3M | $426.4M | 2024 |
| Stargazer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $28.5M | $967.8M | 2018 |
| Arrakis Therapeutics, Inc. | — | Biotechnology | Series A | $28.2M | $542.3M | 2019 |
Richard Gaster at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Gaster on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 1 | 16 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| John Wagner | 1 | 10 |
| Srinivas Akkaraju | 1 | 10 |
| Jens Eckstein | 1 | 8 |
| Alan Colowick | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Ben Zadik | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Michael Gilman | 1 | 6 |
| Raj Parekh | 1 | 5 |
| Martin Edwards | 1 | 5 |
| Steven Elms | 1 | 5 |
| David Lowe | 1 | 5 |
| Andrew Sinclair | 1 | 5 |
| James B. Tananbaum | 1 | 4 |
| Mehdi Khodadad | 1 | 3 |
| Colin Walsh | 1 | 3 |
| Andrew Phillips | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.